Skip to main content
Peptide StackRecoveryEmerging EvidenceEducational · Not medical advice

KPV + Larazotide: Gut Barrier & Anti-Inflammatory

KPV, a C-terminal tripeptide fragment of alpha-MSH, is researched for its MC1R-mediated anti-inflammatory action specifically in the gastrointestinal tract. Larazotide acetate (AT-1001) is investigated as a tight-junction regulator that reduces intestinal permeability. The combination is explored for supporting gut barrier integrity and managing mucosal inflammatory signaling.

2
Compounds
Emerging
Evidence Level
2
Research Refs
Recovery
Primary Goal

Mechanism

Compound 1Recovery

KPV

Alpha-MSH C-terminal tripeptide researched for activating MC1R receptors in intestinal epithelial cells to reduce pro-inflammatory cytokine production locally in the GI tract.

+
Compound 2Recovery

Larazotide

Tight-junction regulatory peptide researched for reducing intestinal permeability by modulating zonulin-mediated tight junction dynamics in intestinal epithelial cells.

Synergistic Effect

Dual-pathway activation

KPV × Larazotide

Safety Notes

Larazotide has been studied in human clinical trials for celiac disease and intestinal permeability with a well-documented safety profile. KPV research is primarily preclinical and early-phase. Neither peptide is associated with systemic immunosuppression at research doses.

Research References

Per-component source only — no combination study exists

Established

Larazotide acetate for persistent symptoms of celiac disease despite a gluten-free diet

Gastroenterology 2015PMID 25683116
Emerging

The tripeptide KPV suppresses intestinal inflammation via melanocortin-1 receptor

Biochem Pharmacol 2006
Browse all →

⚠ Educational Use OnlyPeptideBase provides educational research tools and provider discovery. It does not provide medical advice, diagnosis, treatment, prescribing guidance, or dosing instructions. Consult a qualified healthcare professional before making health decisions.

Newsletter

The Peptide Research Digest

New providers, emerging stacks, and research developments — weekly.

No spam. Unsubscribe anytime. Privacy policy.